Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products

The members of the SIG on the hospital pharmacist's preparedness for in-vivo gene therapy medicinal products (financially supported by Pfizer) are looking at the requirements for the handling, preparations and administration of gene therapy products throughout Europe in order to provide guidance and training materials to hospital pharmacists.

 

Survey investigating the preparedness of hospital pharmacies for in-vivo gene therapy medicinal products

Due to the number of licensed formulations on the horizon, the SIG hoped to obtain information on the preparedness of hospital pharmacy departments for the delivery of in-vivo gene therapy medicines to their patients with the helpf of a survey. The survey included questions touching on the hospital pharmacy facilities and the pharmacists working in these facilities. Hospital pharmacists that are not yet working with in-vivo gene therapies were also encouraged to participate in this survey. The survey closed in June 2022.

 

Last update: 6 September 2022